VAR - Varian Medical Systems, Inc.

NYSE - NYSE Delayed Price. Currency in USD
130.65
-0.25 (-0.19%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close 130.90
Open 129.58
Bid 130.83 x 800
Ask 130.91 x 1100
Day's Range 129.38 - 132.25
52 Week Range 101.42 - 142.50
Volume 636,730
Avg. Volume 606,668
Market Cap 11.882B
Beta (3Y Monthly) 0.89
PE Ratio (TTM) 31.74
EPS (TTM) N/A
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date 1998-12-02
1y Target Est N/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire 3 days ago

    Varian Announces Incremental Gross Impact of New Tariffs

    PALO ALTO, Calif., May 16, 2019 /PRNewswire/ -- Varian (VAR) today announced preliminary estimates of the incremental gross impact of new tariffs. Over the past week, the US increased tariffs on certain goods (US List 3), and imposed new tariffs on certain other goods (US List 4), imported from China.  Subsequently, China implemented a retaliatory increase in tariffs on certain goods imported from the US (responding to the US List 3 action).  Management has preliminarily estimated the gross impact of these new tariffs to be in the range of $3M to $5M.

  • PR Newswire 5 days ago

    Cyclotron for Varian ProBeam Compact Proton Therapy System Installed at New Treatment Center in Singapore

    The cyclotron is a core piece of equipment in the ProBeam proton therapy system. This installation marks a key milestone for the first proton therapy center in Singapore, ASEAN, Australia and New Zealand.

  • PR Newswire 6 days ago

    Papua New Guinea Hospital Selects Varian Cancer Care Solution

    PALO ALTO, Calif., May 13, 2019 /PRNewswire/ -- Varian (VAR) today announced it was selected by Port Moresby General Hospital (PMGH) in Papua New Guinea to equip its cancer treatment center with the Halcyon™ radiotherapy system, as well as the ARIA® oncology information system and Eclipse™ treatment planning system. The Halcyon system simplifies and enhances virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT), including improved patient comfort and shortening the time from installation to first-treatment without sacrificing quality. The Halcyon system is well-suited to treat a majority of cancer patients, offering advanced treatments for lung, prostate, breast, head & neck, and many other forms of cancer.

  • PR Newswire 10 days ago

    Varian Acquires CyberHeart

    The CyberHeart acquisition secures significant intellectual property/patents that cover the use of radiation in the heart. Early positive clinical evidence suggests that cardiac radioablation has the potential to offer hope to patients with intractable cardiac arrhythmias. Acquisitions are a critical step in Varian's long-term strategy to become a global leader in multi-disciplinary, integrated cancer solutions as well as other applications of radiation medicine.

  • PR Newswire 10 days ago

    Varian Selected to Equip Two Proton Therapy Centers in Norway

    PALO ALTO, Calif. , May 9, 2019 /PRNewswire/ -- Following a comprehensive evaluation by Sykehusbygg HF Norway and regional health authorities, Varian (NYSE: VAR) was selected to equip two proton therapy ...

  • PR Newswire 10 days ago

    Varian and Shandong Cancer Hospital Form Proton Therapy Clinical Application and Research Partnership in China

    PALO ALTO, Calif. and JINAN, China, May 9, 2019 /PRNewswire/ -- Varian (VAR) today announced it has signed a strategic cooperation framework agreement with Shandong Cancer Hospital in China, for proton therapy clinical application and research. The agreement signing ceremony on May 9th in Jinan, China was attended by Professor Yu Jinming, academician of the Chinese Academy of Engineering and president of Shandong Cancer Hospital & Institute, Kolleen Kennedy, president, Proton Solutions and chief growth officer of Varian, and Dr. Zhang Xiao, vice president and head of Varian Greater China.

  • PR Newswire 12 days ago

    Varian to Attend Upcoming Investor Events

    PALO ALTO, Calif. , May 7, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced that it will be attending the UBS Global Healthcare Conference ( May 20-22 ) and the 2019 RBC Capital Markets Healthcare ...

  • PR Newswire 19 days ago

    South Africa Hospital Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System

    PALO ALTO, Calif. and CAPE TOWN, South Africa, April 30, 2019 /PRNewswire/ -- Varian (VAR) announced Groote Schuur Hospital in Cape Town, South Africa is the first hospital in Africa to deliver High Dose Rate (HDR) brachytherapy treatments with the Bravos™ afterloader system. Bravos is an integrated system designed to improve the patient and clinic experience by simplifying brachytherapy treatments and providing greater workflow efficiency. HDR brachytherapy involves delivering radiotherapy by temporarily placing a tiny radioactive source directly into the tumor or other targeted area.

  • PR Newswire 20 days ago

    Ofuna Chuo Hospital Delivers First Varian Halcyon System Treatments in Japan

    PALO ALTO, Calif., April 29, 2019 /PRNewswire/ -- Varian (VAR) today announced Ofuna Chuo Hospital, Kamakura City, Kanagawa Prefecture, Japan is the first clinic in the country to begin treating cancer patients using the Halcyon™ radiotherapy system. The Halcyon system simplifies and enhances virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT), including improved patient comfort and shortening the time from installation to first-treatment without sacrificing quality.

  • PR Newswire 23 days ago

    Varian Announces Global Clinical Consortium to Develop Evidence-based Protocols for Adaptive Radiotherapy

    PALO ALTO, Calif. , April 26, 2019 /PRNewswire/ -- Bringing together a global community of clinicians and scientists from leading cancer clinics to develop best practices for adaptive radiotherapy based ...

  • PR Newswire 25 days ago

    Varian Reports Results for Second Quarter of Fiscal Year 2019

    Raises Revenue Guidance for Fiscal Year 2019 PALO ALTO, Calif. , April 24, 2019 /PRNewswire/ -- Second Quarter 2019 Summary –    Oncology gross orders grew 15% in dollars, or 18% in constant currency –    ...

  • PR Newswire 26 days ago

    First Varian Halcyon Treatments in Kenya Begin at Nairobi West Hospital

    PALO ALTO, Calif. and NAIROBI, Kenya, April 23, 2019 /PRNewswire/ -- Varian (VAR) today announced that The Nairobi West Hospital in Nairobi, Kenya is the first clinic in the country and in West, Central, and East Africa to begin treating cancer patients using the Halcyon™ radiotherapy system. The Halcyon system simplifies and enhances virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT), including improved patient comfort and shortening the time from installation to first-treatment without sacrificing quality. The system is well suited to treat a majority of cancer patients, offering advanced treatments for lung, prostate, breast, head & neck, and many other forms of cancer.

  • PR Newswire 26 days ago

    Varian to Demonstrate Advanced Cancer Care Solutions at ESTRO 38

    PALO ALTO, Calif. , April 23, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced it will be showcasing its new single-room proton therapy system, ProBeam ® 360°, and the Bravos ™ afterloader system ...

  • PR Newswire last month

    Varian Installs Cyclotron for ProBeam Proton Therapy System at Hefei Ion Medical Center in China

    PALO ALTO, Calif. and HEFEI, China , April 8, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced the installation of the cyclotron for the Varian ProBeam ®  proton therapy system at Hefei Ion Medical ...

  • PR Newswire last month

    Varian Opens Office in South Africa to Support Regional Growth

    PALO ALTO, Calif. , April 4, 2019 /PRNewswire/ -- At a grand opening ceremony held March 8th , the Varian office in Hertford Office Park, Midrand, Johannesburg, South Africa was officially inaugurated. ...

  • PR Newswire 2 months ago

    Varian Discloses First Preclinical Results of Potential Major Breakthrough in Cancer Treatment

    PALO ALTO, Calif., April 3, 2019 /PRNewswire/ -- At the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA, Varian (VAR), in partnership with the University of Maryland School of Medicine's Department of Radiation Oncology and the Maryland Proton Treatment Center, presented publicly the first pre-clinical results of its research on ultra-high dose rate cancer treatments with protons. Known as Flash therapy, it is a non-invasive therapy for cancer delivering high doses of radiation in ultra-high-speeds (less than 1 second) and represents the potential for a major breakthrough in the treatment of cancer. The preclinical Flash therapy results presented at AACR showed reduced toxicity in healthy tissues and organs.

  • PR Newswire 2 months ago

    Beacon Hospital Treats First Patient in Malaysia on Varian Halcyon System

    PALO ALTO, Calif., April 2, 2019 /PRNewswire/ -- Varian (VAR) today announced a 62-year-old male with thyroid cancer was the first patient in Malaysia to be treated on the Halcyon™ system at Beacon Hospital in Selangor. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT), including improved patient comfort and shortening the time from installation to first-treatment without sacrificing quality. The system is well suited to treat a majority of cancer patients, offering advanced treatments for lung, prostate, breast, head & neck, and many other forms of cancer.

  • PR Newswire 2 months ago

    Korea University Medical Center Completes First Varian Halcyon System Treatment in Korea

    PALO ALTO, Calif. and SEOUL, South Korea , March 26, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced a 55-year-old male with liver cancer at the Korea University Medical Center Anam Hospital , ...

  • PR Newswire 2 months ago

    Varian Holds First Meeting of FlashForward Consortium

    PALO ALTO, Calif. , March 21, 2019 /PRNewswire/ -- Building on its market-leading efforts in preclinical research aimed at clinical implementation of Flash therapy, Varian (NYSE: VAR) hosted the first ...

  • PR Newswire 2 months ago

    Varian Announces Second Quarter Fiscal Year 2019 Earnings Release Date and Upcoming Investor Event

    PALO ALTO, Calif. , March 11, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced its second quarter fiscal year 2019 earnings release date and upcoming investor event. Second Quarter Fiscal Year 2019 ...

  • PR Newswire 2 months ago

    Varian and Tata Trusts Sign Framework Agreement for Advanced Cancer Care Solutions to Address Growing Need in India

    PALO ALTO, California and MUMBAI, India, March 11, 2019 /PRNewswire/ -- With an estimated 1.8 million new cancer cases a year in India expected by 2025[1], Tata Trusts and Varian (VAR) announced the signing of a framework agreement intended to increase patient access to advanced radiation therapy treatments in the country. The three-year agreement is focused on world-class cancer care delivery through the installation of radiation therapy treatment systems across India where Varian has been selected as the preferred supplier by Tata Trusts.

  • GlobeNewswire 3 months ago

    New Research Coverage Highlights Micron Technology, Varian Medical, St. Joe, Himax Technologies, Aerie Pharmaceuticals, and Hexcel — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • PR Newswire 3 months ago

    Varian and Danish Center for Particle Therapy Announce Grand Opening and First Patient Treatments

    PALO ALTO, Calif. , Feb. 28, 2019 /PRNewswire/ --  In a ceremony officiated by the Regional Council of Central Denmark Region, Anders Kühnau, and attended by both the Danish Prime Minister Lars Løkke Rasmussen, ...